ESMO ECCO 2015: les temps forts de l'immunothérapie et des thérapies ciblées

Clément Bonnet; Guillaume Beinse; Luc Cabel; Delphine Cochereau; Pernelle Lavaud; Pauline Rochefort; Emeline Tabouret; Anthony Turpin; Loic Verlingue; Cécile Vicier; Christophe Massard

doi:10.1016/j.bulcan.2016.04.001

ESMO ECCO 2015: les temps forts de l'immunothérapie et des thérapies ciblées

Clément Bonnet, Guillaume Beinse, Luc Cabel, Delphine Cochereau, Pernelle Lavaud, Pauline Rochefort, Emeline Tabouret, Anthony Turpin, Loic Verlingue, Cécile Vicier, Christophe Massard

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.

Titre traduit de la contribution	ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies
langue originale	Français
Pages (de - à)	594-603
Nombre de pages	10
journal	Bulletin du Cancer
Volume	103
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.bulcan.2016.04.001
état	Publié - 1 juin 2016

mots-clés

Early phase studies
Immunotherapies
Personalized medicine
Targeted therapies

Accès au document

10.1016/j.bulcan.2016.04.001

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{457a6c9830f645a1bd85932dce3fb7bb,

title = "ESMO ECCO 2015: les temps forts de l'immunoth{\'e}rapie et des th{\'e}rapies cibl{\'e}es",

abstract = "The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.",

keywords = "Early phase studies, Immunotherapies, Personalized medicine, Targeted therapies",

author = "Cl{\'e}ment Bonnet and Guillaume Beinse and Luc Cabel and Delphine Cochereau and Pernelle Lavaud and Pauline Rochefort and Emeline Tabouret and Anthony Turpin and Loic Verlingue and C{\'e}cile Vicier and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2016 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer. Publi{\'e} par Elsevier Masson SAS. Tous droits r{\'e}serv{\'e}s.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.bulcan.2016.04.001",

language = "Fran{\c c}ais",

volume = "103",

pages = "594--603",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "6",

}

TY - JOUR

T1 - ESMO ECCO 2015

T2 - les temps forts de l'immunothérapie et des thérapies ciblées

AU - Bonnet, Clément

AU - Beinse, Guillaume

AU - Cabel, Luc

AU - Cochereau, Delphine

AU - Lavaud, Pernelle

AU - Rochefort, Pauline

AU - Tabouret, Emeline

AU - Turpin, Anthony

AU - Verlingue, Loic

AU - Vicier, Cécile

AU - Massard, Christophe

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.

AB - The ESMO/ECC congress (European Society for Medical Oncology/European Cancer Congress) took place in Vienna, Austria, September 25-29. The main topic of the conference was immunotherapies especially in advanced kidney cancer with nivolumab in phase III and in metastatic lung cancer with atezolizumab in phase II. Targeted therapies were also highlighted with cabozantinib proposed in advanced renal cancer or everolimus in differenciated neuroendocrine tumors grade 1 or 2. Furthermore the current challenges remain unchanged: improving patients' care through better selection and finding biomarkers using simple samples (blood or urine). Also early phases and personalized medicine found their place in the different presentations and were highlighted largely bringing new approaches in the treatment of metastatic patients.

KW - Early phase studies

KW - Immunotherapies

KW - Personalized medicine

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84975137944&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2016.04.001

DO - 10.1016/j.bulcan.2016.04.001

M3 - Article

C2 - 27229364

AN - SCOPUS:84975137944

SN - 0007-4551

VL - 103

SP - 594

EP - 603

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 6

ER -